Impact of pegloticase on patient outcomes in refractory gout: current perspectives

about

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

Item

http://www.wikidata.org/entity/Q58698860

description

scientific article published on 18 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

@en

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

@nl

type

Item

label

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

@en

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

@nl

prefLabel

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

@en

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

@nl

P1476

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

@en

P2093

Filipa Farinha

http://www.w3.org/2001/XMLSchema#string

Renata Aguiar

http://www.w3.org/2001/XMLSchema#string

Rita N Cunha

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Pathogenesis of Gout

Uricosuric medications for chronic gout

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

2016 updated EULAR evidence-based recommendations for the management of gout.

What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions.

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Tria

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

P304

141-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OARRR.S176951

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30425593

http://www.w3.org/2001/XMLSchema#string

P921

Infections

P932

6201997

http://www.w3.org/2001/XMLSchema#string